Kymera Reports Narrower Loss In Q2 As Collaboration Revenue Jumps

Kymera Therapeutics reported narrower Q2 net loss, driven primarily by higher collaboration revenue. The company also outlined business highlights and upcoming milestones, suggesting improving operating momentum. Overall, results and forward milestones are modest positives likely to move the stock to some extent.

Analysis

Kymera Therapeutics reported narrower Q2 net loss, driven primarily by higher collaboration revenue. The company also outlined business highlights and upcoming milestones, suggesting improving operating momentum. Overall, results and forward milestones are modest positives likely to move the stock to some extent.